Research Study on Whether a Combination of 2 Medicines Works in People With Non-alcoholic Steatohepatitis (NASH)
Brief description of study
This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH).
NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. It also helps with weight loss and may reduce liver damage, and so prevent future liver complications. It works in a different way to NNC0194 0499. The 2 medicines may work better together than on their own.
The study will also look at a combination of semaglutide and another weight-loss medicine called NNC0174-0833, which may be another treatment option for NASH.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Non-alcoholic Steatohepatitis,NASH
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male or Female Age 18 or older Histological evidence of NASH
Updated on
09 Mar 2024.
Study ID: 849168
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting